Overview of CAR-T Cells and Toxicities SPOC
CAR-T therapy is expanding as a therapeutic option both in clinical trials and FDA approved commercial products for cancer patients. This lecture will review the current treatments and their use in patients with hematologic malignancies.
These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, and others who are interested in care of patients with cancer in North Carolina.
- Describe the currently available and new indications of FDA approved CAR-T products
- Discuss current trends in side effect management and patient care considerations
- Discuss future directions of CAR-T therapy in commercial and trial products, including active trials at UNC
Taking the Course
To continue, click the button Take Course.
If you do not see the button, please ensure that you are logged in. If you are logged in and still don't see the button, please contact us at email@example.com or (919) 455–1000.
Natalie Grover, MD
Assistant Professor of Medicine
Faith Brianne Buchanan, PA-C
Physician Assistant, UNC Bone Marrow Transplant and Cellular Therapy Program
Presenter Disclosure Information
Natalie Grover, MD, and Faith Brianne Buchanan, PA-C, have no relevant financial relationships with commercial interests as defined by the ACCME.
This Non-Credit Course does NOT have accreditation for continuing education credits.
The course offers only general participation certificates.
- 1.00 Participation
UNC Lineberger Cancer Network certificate of participation.
Tim Poe, Director of Telehealth